Brief: Gubra Expects 10-15% Organic Revenue Growth In CRO In 2024
28/02/2024 06:43
Feb 28 (Reuters) - Gubra A/S GUBRA.CO :
* WE EXPECT TO CONTINUE HIGH GROWTH IN CRO BUSINESS IN 2024
AND
GUIDE FOR 10-15% ORGANIC REVENUE GROWTH COMPARED TO RECORD-HIGH
LEVEL IN 2023
* FOR D&P, OUR FOCUS FOR 2024 IS ON CONTINUING TO STRENGTHEN
OUR
RESEARCH AND DEVELOPMENT PIPELINE WITH INNOVATIVE NOVEL DRUG
CANDIDATES AND ADVANCE OUR PARTNERSHIP DISCUSSIONS
* ANOTHER KEY FOCUS IS OF COURSE ONGOING PHASE 1 TRIAL FOR
GUBAMY
WHERE WE EXPECT TO COMPLETE ENROLLMENT BY MID-2024
* EXPANSION OF ITS OFFERINGS WILL CONTINUE IN 2024
* IN TERMS OF CRO EARNINGS, WE EXPECT AN ADJUSTED
EBIT-MARGIN
BETWEEN 25-28%.
* OUR MID-TERM TARGET REMAINS 35-40%, BUT GUBRA IS STILL
INVESTING
IN NEW DISEASE AREAS AND NEW MODELS WHEREFORE EBIT IN 2024
REMAINS BELOW THAT FIGURE
Source text for Eikon: ID:nMFN9MgZnk
Further company coverage: GUBRA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))